LM11A-31 or C31

Neuron ConnectionsSummarized from “Alzheimer’s From A New Angle” by Alice Park, originally printed in Time Magazine.

A new drug called LM11A-31 or C31 as it’s known to its researcher Dr. Frank Longo from Stanford University School of Medicine is being tested right now in clinical trials. This drug is attacking the Alzheimer’s dilemma from a new angle. Instead of trying to dissolve the harmful proteins, amyloid plaques and tau protein tangles, he is using this nerve growth factor to bolster the brain neurons in order to help protect them from the damaging protein onslaught. If the brain can maintain its cognitive function longer despite the protein build-up, perhaps that is the key. The drug in mice actually showed progression from a plaques and tangled brain to a healthy one. Although we know that many different scenarios that were successful in the testing of mice did not prove helpful in the human, they are hopeful that this will work. People with higher levels of brain nerve growth factor (BDNF) do fare better in keeping more cognitive function and this gives them a cushion of reserve against harmful proteins.

The drug has survived the Phase I Trials that showed that it is safe with minimal side-effects in humans. Now in Phase II Trials it has to be shown to actually improve patients’ cognition. Dr. Longo of PharmatrophiX hopes that in the future this compound will be one of a few drugs that will be taken as a “cocktail” for those with dementia….this drug to bolster the neurons and other drugs to break up the harmful proteins.

Let’s hope this shows some promise. It’s about time researchers found something to give us some hope!

2 thoughts on “LM11A-31 or C31”

  1. After failures ex 1500 trial pills against Alzheimer, our hope was & is on Dr Longo’s LM11A-31 pill.
    It has been tested in Sweden & I guess is on a “to FDA äpproval,”path, – but nobody informs us,
    the general public on what its status is at present. Time Magazine wrote about PharmatrophiX’s
    LM11A-31 pill on Febr 22, 2016, only to follow up with an article in 2018 about the testing of (the0 renewed Aducanumab pill by a 77 yrs old couple. Aducanumab was already tested in Holland in 2016, without results. So, why can nobody inform the world at large what the state of Dr Longo’s pill
    is at present; time is running out for a lot of people!

    1. Hi Jan,
      I understand your frustration with research. Presently there is a big study taking place in selected cities all across the country (Through Banner Institute in Arizona) with crenezumab and those of the “paisa” of Columbia, and others with genetic predispositions before the dementia is visible to see if the drug will decrease amyloid in the brain, and thus push back the time at which the symptoms are displayed. Read The Inheritance by Niki Kapsambelis.

      For those of us with the genetic predisposition APOE4 and PS1-2 we all are on pins and needles as to whether research will save us from the inevitable outcome. Our family waited for 20 years 7 years ago … and we are still waiting to be “saved”.

Leave a Reply

Your email address will not be published. Required fields are marked *